purchase customization

1 Study Coverage
1.1 Human Vaccines Administered Orally Product Introduction
1.2 Market by Type
1.2.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.3 Market by Application
1.3.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Public
1.3.3 Private
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Human Vaccines Administered Orally Sales Estimates and Forecasts 2017-2028
2.2 Global Human Vaccines Administered Orally Revenue Estimates and Forecasts 2017-2028
2.3 Global Human Vaccines Administered Orally Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Human Vaccines Administered Orally Sales by Region
2.4.1 Global Human Vaccines Administered Orally Sales by Region (2017-2022)
2.4.2 Global Sales Human Vaccines Administered Orally by Region (2023-2028)
2.5 Global Human Vaccines Administered Orally Revenue by Region
2.5.1 Global Human Vaccines Administered Orally Revenue by Region (2017-2022)
2.5.2 Global Human Vaccines Administered Orally Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Human Vaccines Administered Orally Sales by Manufacturers
3.1.1 Global Top Human Vaccines Administered Orally Manufacturers by Sales (2017-2022)
3.1.2 Global Human Vaccines Administered Orally Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Vaccines Administered Orally in 2021
3.2 Global Human Vaccines Administered Orally Revenue by Manufacturers
3.2.1 Global Human Vaccines Administered Orally Revenue by Manufacturers (2017-2022)
3.2.2 Global Human Vaccines Administered Orally Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Human Vaccines Administered Orally Revenue in 2021
3.3 Global Human Vaccines Administered Orally Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Human Vaccines Administered Orally Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Vaccines Administered Orally Sales by Type
4.1.1 Global Human Vaccines Administered Orally Historical Sales by Type (2017-2022)
4.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Type (2023-2028)
4.1.3 Global Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
4.2 Global Human Vaccines Administered Orally Revenue by Type
4.2.1 Global Human Vaccines Administered Orally Historical Revenue by Type (2017-2022)
4.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Type (2023-2028)
4.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
4.3 Global Human Vaccines Administered Orally Price by Type
4.3.1 Global Human Vaccines Administered Orally Price by Type (2017-2022)
4.3.2 Global Human Vaccines Administered Orally Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Human Vaccines Administered Orally Sales by Application
5.1.1 Global Human Vaccines Administered Orally Historical Sales by Application (2017-2022)
5.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Application (2023-2028)
5.1.3 Global Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
5.2 Global Human Vaccines Administered Orally Revenue by Application
5.2.1 Global Human Vaccines Administered Orally Historical Revenue by Application (2017-2022)
5.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Application (2023-2028)
5.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
5.3 Global Human Vaccines Administered Orally Price by Application
5.3.1 Global Human Vaccines Administered Orally Price by Application (2017-2022)
5.3.2 Global Human Vaccines Administered Orally Price Forecast by Application (2023-2028)
6 North America
6.1 North America Human Vaccines Administered Orally Market Size by Type
6.1.1 North America Human Vaccines Administered Orally Sales by Type (2017-2028)
6.1.2 North America Human Vaccines Administered Orally Revenue by Type (2017-2028)
6.2 North America Human Vaccines Administered Orally Market Size by Application
6.2.1 North America Human Vaccines Administered Orally Sales by Application (2017-2028)
6.2.2 North America Human Vaccines Administered Orally Revenue by Application (2017-2028)
6.3 North America Human Vaccines Administered Orally Market Size by Country
6.3.1 North America Human Vaccines Administered Orally Sales by Country (2017-2028)
6.3.2 North America Human Vaccines Administered Orally Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Human Vaccines Administered Orally Market Size by Type
7.1.1 Europe Human Vaccines Administered Orally Sales by Type (2017-2028)
7.1.2 Europe Human Vaccines Administered Orally Revenue by Type (2017-2028)
7.2 Europe Human Vaccines Administered Orally Market Size by Application
7.2.1 Europe Human Vaccines Administered Orally Sales by Application (2017-2028)
7.2.2 Europe Human Vaccines Administered Orally Revenue by Application (2017-2028)
7.3 Europe Human Vaccines Administered Orally Market Size by Country
7.3.1 Europe Human Vaccines Administered Orally Sales by Country (2017-2028)
7.3.2 Europe Human Vaccines Administered Orally Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Human Vaccines Administered Orally Market Size by Type
8.1.1 Asia Pacific Human Vaccines Administered Orally Sales by Type (2017-2028)
8.1.2 Asia Pacific Human Vaccines Administered Orally Revenue by Type (2017-2028)
8.2 Asia Pacific Human Vaccines Administered Orally Market Size by Application
8.2.1 Asia Pacific Human Vaccines Administered Orally Sales by Application (2017-2028)
8.2.2 Asia Pacific Human Vaccines Administered Orally Revenue by Application (2017-2028)
8.3 Asia Pacific Human Vaccines Administered Orally Market Size by Region
8.3.1 Asia Pacific Human Vaccines Administered Orally Sales by Region (2017-2028)
8.3.2 Asia Pacific Human Vaccines Administered Orally Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Human Vaccines Administered Orally Market Size by Type
9.1.1 Latin America Human Vaccines Administered Orally Sales by Type (2017-2028)
9.1.2 Latin America Human Vaccines Administered Orally Revenue by Type (2017-2028)
9.2 Latin America Human Vaccines Administered Orally Market Size by Application
9.2.1 Latin America Human Vaccines Administered Orally Sales by Application (2017-2028)
9.2.2 Latin America Human Vaccines Administered Orally Revenue by Application (2017-2028)
9.3 Latin America Human Vaccines Administered Orally Market Size by Country
9.3.1 Latin America Human Vaccines Administered Orally Sales by Country (2017-2028)
9.3.2 Latin America Human Vaccines Administered Orally Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Human Vaccines Administered Orally Market Size by Type
10.1.1 Middle East and Africa Human Vaccines Administered Orally Sales by Type (2017-2028)
10.1.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Type (2017-2028)
10.2 Middle East and Africa Human Vaccines Administered Orally Market Size by Application
10.2.1 Middle East and Africa Human Vaccines Administered Orally Sales by Application (2017-2028)
10.2.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Application (2017-2028)
10.3 Middle East and Africa Human Vaccines Administered Orally Market Size by Country
10.3.1 Middle East and Africa Human Vaccines Administered Orally Sales by Country (2017-2028)
10.3.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Overview
11.1.3 Merck Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Merck Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Lanzhou Institute
11.4.1 Lanzhou Institute Corporation Information
11.4.2 Lanzhou Institute Overview
11.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Lanzhou Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Lanzhou Institute Recent Developments
11.5 Serum Institute
11.5.1 Serum Institute Corporation Information
11.5.2 Serum Institute Overview
11.5.3 Serum Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Serum Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Serum Institute Recent Developments
11.6 Valneva
11.6.1 Valneva Corporation Information
11.6.2 Valneva Overview
11.6.3 Valneva Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Valneva Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Valneva Recent Developments
11.7 Shanghai United Cell
11.7.1 Shanghai United Cell Corporation Information
11.7.2 Shanghai United Cell Overview
11.7.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shanghai United Cell Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai United Cell Recent Developments
11.8 Bibcol
11.8.1 Bibcol Corporation Information
11.8.2 Bibcol Overview
11.8.3 Bibcol Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Bibcol Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bibcol Recent Developments
11.9 PaxVax
11.9.1 PaxVax Corporation Information
11.9.2 PaxVax Overview
11.9.3 PaxVax Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 PaxVax Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 PaxVax Recent Developments
11.10 Vabiotech
11.10.1 Vabiotech Corporation Information
11.10.2 Vabiotech Overview
11.10.3 Vabiotech Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Vabiotech Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Vabiotech Recent Developments
11.11 Tiantan Biological
11.11.1 Tiantan Biological Corporation Information
11.11.2 Tiantan Biological Overview
11.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Tiantan Biological Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Tiantan Biological Recent Developments
11.12 EuBiologics
11.12.1 EuBiologics Corporation Information
11.12.2 EuBiologics Overview
11.12.3 EuBiologics Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 EuBiologics Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 EuBiologics Recent Developments
11.13 Panacea Biotec Ltd
11.13.1 Panacea Biotec Ltd Corporation Information
11.13.2 Panacea Biotec Ltd Overview
11.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Panacea Biotec Ltd Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Panacea Biotec Ltd Recent Developments
11.14 Bio-Med
11.14.1 Bio-Med Corporation Information
11.14.2 Bio-Med Overview
11.14.3 Bio-Med Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Bio-Med Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Bio-Med Recent Developments
11.15 Halfkin Bio-Pharmaceuticals
11.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
11.15.2 Halfkin Bio-Pharmaceuticals Overview
11.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Vaccines Administered Orally Industry Chain Analysis
12.2 Human Vaccines Administered Orally Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Vaccines Administered Orally Production Mode & Process
12.4 Human Vaccines Administered Orally Sales and Marketing
12.4.1 Human Vaccines Administered Orally Sales Channels
12.4.2 Human Vaccines Administered Orally Distributors
12.5 Human Vaccines Administered Orally Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Human Vaccines Administered Orally Industry Trends
13.2 Human Vaccines Administered Orally Market Drivers
13.3 Human Vaccines Administered Orally Market Challenges
13.4 Human Vaccines Administered Orally Market Restraints
14 Key Findings in The Global Human Vaccines Administered Orally Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer